MEDICUS PHARMA LTD. Operating Cash Flow
MEDICUS PHARMA LTD. (MDCX) reported Operating Cash Flow of -$15.95 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-12
- MEDICUS PHARMA LTD. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$6.98M.
- MEDICUS PHARMA LTD. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$8.97M.
- MEDICUS PHARMA LTD. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$6.61M.
- MEDICUS PHARMA LTD. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$6.76M.
- MEDICUS PHARMA LTD. net cash provided by (used in) operating activities for fiscal 2025 was -$22.78M.
- MEDICUS PHARMA LTD. net cash provided by (used in) operating activities for fiscal 2024 was -$10.25M.
- MEDICUS PHARMA LTD. net cash provided by (used in) operating activities for fiscal 2023 was -$4.16M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$6.98M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | -$15.95M 10-Q · filed 2026-08-12 | -$22.56M derived: sum of 3 quarters · filed 2026-08-12 | -$29.32M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | -$8.97M 10-Q · filed 2026-05-14 | -$15.58M derived: sum of 2 quarters · filed 2026-05-14 | -$22.34M derived: sum of 3 quarters · filed 2026-05-14 | -$27.81M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | -$6.61M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | -$13.37M derived: sum of 2 quarters · filed 2026-03-25 | -$18.84M derived: sum of 3 quarters · filed 2026-08-12 | -$22.78M 10-K · filed 2026-03-25 |
| 2025-09-30 | -$6.76M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | -$12.23M derived: sum of 2 quarters · filed 2026-08-12 | -$16.17M 10-Q · filed 2025-11-14 | -$19.36M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | -$5.47M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | -$9.41M 10-Q · filed 2026-08-12 | -$12.60M derived: sum of 3 quarters · filed 2026-08-12 | -$15.70M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | -$3.94M 10-Q · filed 2026-05-14 | -$7.13M derived: sum of 2 quarters · filed 2026-05-14 | -$10.23M derived: sum of 3 quarters · filed 2026-05-14 | -$13.01M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | -$3.19M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | -$6.29M derived: sum of 2 quarters · filed 2026-03-25 | -$9.07M derived: sum of 3 quarters · filed 2026-03-25 | -$10.25M 10-K · filed 2026-03-25 |
| 2024-09-30 | -$3.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | -$5.88M derived: sum of 2 quarters · filed 2025-11-14 | -$7.06M 10-Q · filed 2025-11-14 | |
| 2024-06-30 | -$2.78M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | -$3.95M 10-Q · filed 2025-08-11 | ||
| 2024-03-31 | -$1.18M 10-Q · filed 2025-05-12 | |||
| 2023-12-31 | -$4.16M 10-K · filed 2025-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B |